Cancer (Solid Tumors), Interaction Drug Food
Conditions
Keywords
dietary supplements, cancer, Anticancer Therapy
Brief summary
The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies. The main questions it aims to answer : * What is the prevalence of dietary supplement use among cancer patients, and what is their tolerance profile? * Are there any potential drug interactions between dietary supplements and anticancer medications? Participants will: * Provide sociodemographic information, including age, sex, educational level, and other relevant characteristics. * Report their use of dietary supplements, including the types of supplements consumed (e.g., vitamins, minerals, herbal products), dietary practices, frequency and duration of use, and reasons for consumption (e.g., medical recommendation or self-medication). * Report any perceived adverse effects related to dietary supplement use to assess tolerance. * Allow the collection of relevant clinical data from their medical records, including cancer type, ongoing anticancer treatments, and treatment-related adverse effects.
Interventions
BEHAVIORALDietary Supplement Use Assessment
Participants will complete a structured face-to-face questionnaire on dietary supplement use, reasons for Use, frequency and duration of use, perceived adverse effects, and concomitant anticancer treatments.
Sponsors
Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with cancer and receiving medical anticancer treatment, including chemotherapy, hormone therapy, immunotherapy, and targeted therapies. * Current or recent use of one or more dietary supplements (e.g., vitamins, minerals, herbal products, or other nutritional supplements). * Adult patients : \>=18
Exclusion criteria
* Patients unable to complete the study questionnaire because of cognitive impairment or a deteriorated health condition. * Failure or refusal to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of Dietary Supplement Use and Tolerance | At enrollment | Assessment of the prevalence of dietary supplement use among cancer patients and evaluation of adverse effects associated with dietary supplement consumption. |
| Potential Drug-Supplement Interactions | At enrollment or single study visit | Assessment of potential interactions between dietary supplements and anticancer medications |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Potential Drug-Supplement Interactions Assessed by Artificial Intelligence | At enrollment or Single study visit | Assessment of potential interactions between dietary supplements and anticancer treatments using Hedrine software. |
Countries
Morocco
Contacts
CONTACTSihame Lkhoyaali, Professor of Medical Oncology
CONTACTBadiaa Batlamous
Outcome results
None listed